Studi clinici su HIV a Houston, TX
17 studi su HIV cercano partecipanti presso sedi a Houston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
In reclutamentoStudio osservazionale
- UT Health, Houston
- Thomas Street at Quentin Mease Health Center, Houston
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
In reclutamentoFase 3
- GSK Investigational Site, Houston
ADELANTE: A Randomized Controlled Trial to Improve Engagement in Care for Latinos With HIV
In reclutamento
- Baylor College of Medicine, Houston
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
In reclutamentoFase 2/3
- Saint Hope Foundation, Inc. ( Site 1504), Bellaire · a 7 mi di distanza
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
In reclutamentoFase 1/2
- 5128, Baylor College of Medicine/Texas Children's Hospital Clinical Research Site, Houston
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
In reclutamentoFase 2
- M D Anderson Cancer Center, Houston
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
In reclutamentoFase 1Volontari sani benvenuti
- The Crofoot Research Center, Houston
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
In reclutamento
- University of Texas M.D. Anderson Cancer Center, Houston
Positive Peers Intervention Clinical Trial
In reclutamento
- Thomas Street Clinic, Houston
Screen2Prevent (S2P)
In reclutamentoVolontari sani benvenuti
- Baylor College of Medicine, Houston
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
In reclutamentoFase 2
- UT Health Houston, Houston
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
In reclutamentoFase 2
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
- GSK Investigational Site, Bellaire · a 7 mi di distanza
Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)
In reclutamento
- Houston Methodist Research Institute, Houston
Menopausal HT for Women Living With HIV (HoT)
In reclutamentoFase 4
- Houston AIDS Research Team CRS (31473), Houston
Assessing the Use of MY-RIDE, a Just-in-time Adaptive Intervention, to Improve HIV Prevention and Substance Use in Youth Experiencing Homelessness
In reclutamento
- The University of Texas Health Science Center at Houston, Houston
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
In reclutamentoFase 2
- UT Health Houston, Houston
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
In reclutamentoFase 1/2
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
Studi su HIV in altre città
- Washington, DC22 studi
- New York City, NY19 studi
- Miami, FL17 studi
- Baltimore, MD16 studi
- San Francisco, CA15 studi
- Atlanta, GA14 studi
- Chicago, IL14 studi
- Boston, MA11 studi
- Philadelphia, PA11 studi
- San Diego, CA10 studi
- Los Angeles, CA9 studi
- Seattle, WA8 studi
Altri studi a Houston
- Cancro del polmone non a piccole cellule145 studi
- Cancro al seno126 studi
- Cancro (tutti i tipi)121 studi
- Cancro metastatico104 studi
- Cancro colorettale102 studi
- Cancro ovarico89 studi
- Leucemia mieloide acuta85 studi
- Cancro ai polmoni78 studi
- Cancro alla prostata76 studi
- Cancro dell'endometrio68 studi
- Cancro pancreatico61 studi
- Melanoma59 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.